Xu Bin, Zhu Ke-an, Xu Dabao, Aili Aixingzi
Department of Gynecology, Third Xiangya Hospital of Central South University, 138 Tongzipo Rd, Changsha City, Hunan Province 410013, China.
Reprod Biol Endocrinol. 2014 Jul 7;12:61. doi: 10.1186/1477-7827-12-61.
Female sterilization is the second most commonly used method of contraception in the United States. Female sterilization can now be performed through laparoscopic, abdominal, or hysteroscopic approaches. The hysteroscopic sterilization may be a safer option than sterilization through laparoscopy or laparotomy because it avoids invading the abdominal cavity and undergoing general anaesthesia. Hysteroscopic sterilization mainly includes chemical agents and mechanical devices. Common issues related to the toxicity of the chemical agents used have raised concerns regarding this kind of contraception. The difficulty of the transcervical insertion of such mechanical devices into the fallopian tubes has increased the high incidence of device displacement or dislodgment. At present, Essure® is the only commercially available hysteroscopic sterilization device being used clinically. The system is irreversible and is not effective immediately.
Our new hysteroscopic sterility system consists of nickel-titanium (NiTi) shape memory alloy and a waterproof membrane. The NiTi alloy is covered with two coatings to avoid toxic Ni release and to prevent stimulation of epithelial tissue growth around the oviducts. Because of the shape memory effect of the NiTi alloy, the device works like an umbrella: it stays collapsed at low temperature before placement and opens by the force of shape memory activated by the body temperature after it is inserted hysteroscopically into the interstitial tubal lumen. The rim of the open device will incise into interstitial myometrium during the process of unfolding. Once the device is fixed, it blocks the tube completely. When the patient no longer wishes for sterilization, the device can be closed by perfusing liquid with low temperature into the uterine cavity, followed by prospective hysteroscopic removal. After the device removal, the fallopian tube will revert to its physiological functions.
Currently, experimental and clinical studies are needed to attest the safety, efficiency and reversibility of the novel sterilization device.
If our hypothesis is confirmed, appropriate and reversible contraceptive can be achieved with the device we have designed, which may have significant repercussions for numerous women worldwide.
在美国,女性绝育是第二常用的避孕方法。目前,女性绝育可通过腹腔镜、腹部或宫腔镜途径进行。宫腔镜绝育术可能比腹腔镜或剖腹绝育术更安全,因为它避免了侵入腹腔和接受全身麻醉。宫腔镜绝育主要包括化学制剂和机械装置。与所用化学制剂毒性相关的常见问题引发了对这种避孕方式的担忧。将此类机械装置经宫颈插入输卵管的难度增加了装置移位或脱落的高发生率。目前,埃苏瑞尔(Essure®)是唯一临床上可用的宫腔镜绝育装置。该系统是不可逆的,且并非立即有效。
我们的新型宫腔镜绝育系统由镍钛(NiTi)形状记忆合金和防水膜组成。NiTi合金覆盖有两层涂层,以避免有毒镍的释放,并防止刺激输卵管周围上皮组织生长。由于NiTi合金的形状记忆效应,该装置的工作方式类似于一把伞:在低温下放置前它保持折叠状态,在经宫腔镜插入输卵管间质部管腔后,由体温激活形状记忆力使其打开。打开的装置边缘在展开过程中会切入间质子宫肌层。一旦装置固定,它将完全阻塞输卵管。当患者不再希望绝育时,可通过向宫腔灌注低温液体使装置关闭,随后经宫腔镜取出。装置取出后,输卵管将恢复其生理功能。
目前,需要进行实验和临床研究来证明这种新型绝育装置的安全性、有效性和可逆性。
如果我们的假设得到证实,我们设计的装置可实现合适且可逆的避孕,这可能对全球众多女性产生重大影响。